Delving into the Latest Updates on Nanjing KAEDI Biotherapeutics Co, Ltd. with Synapse

Overview

Tags

Neoplasms

Infectious Diseases

Immune System Diseases

Autologous CAR-T

Bispecific antibody

CAR-NKT

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	10
Infectious Diseases	2
Immune System Diseases	2
Endocrinology and Metabolic Disease	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Autologous CAR-T	3
CAR-T	2
Bispecific antibody	2
CAR-NKT	2
Monoclonal antibody	1

Top 5 Target	Count

CLDN18.2(Claudin 18.2)	3
CD33(Myeloid cell surface antigen CD33)	2
CLDN18.2 x GluN2B x NAMPT x NKG2D x NMDA receptor	1
NKG2D(NKG2-D type II integral membrane protein)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

5

Preclinical

Phase 1 Clinical

1

Phase 2 Clinical

Other

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

KD-025(Nanjing Kaedi Biotechnology Co Ltd) ( NKG2D )	Glioblastoma More	Phase 2 Clinical
KD-496 ( CLDN18.2 x GluN2B x NAMPT x NKG2D x NMDA receptor )	NKG2DL Positive Solid Tumors More	Phase 1
KD-182 ( CLDN18.2 )	Neoplasms More	Preclinical
KD-347N	Neoplasms More	Preclinical
KD-496N	Neoplasms More	Preclinical